(For Research Use Only)
Sedia® HIV-1 LAg-Avidity EIA allows for monitoring the outbreak of new infections in high-risk regions of the world.
Test multiple specimens at the same time.
Coordinate and monitor effectiveness of clinical studies.
Improved accuracy as published in the Recalibration of the Limiting Antigen EIA to Determine Mean Duration of Recent Infection in Divergent HIV-1 Subtypes study.
Mean Duration of Recent Infection of approximately 130 days enables earlier detection of recent HIV-1 infections than other assays. Read More
Want to know more or have any questions? Send us a message!